StockNews.com Begins Coverage on Catalent (NYSE:CTLT)

Equities researchers at StockNews.com started coverage on shares of Catalent (NYSE:CTLTGet Free Report) in a research note issued on Friday. The firm set a “sell” rating on the stock.

Other equities analysts have also recently issued reports about the stock. Stephens restated an “equal weight” rating and set a $63.50 price objective on shares of Catalent in a research report on Thursday, April 4th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $63.50 price objective on shares of Catalent in a report on Tuesday, February 20th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $54.05.

Read Our Latest Stock Report on CTLT

Catalent Trading Down 0.9 %

NYSE CTLT opened at $55.48 on Friday. Catalent has a 1 year low of $31.80 and a 1 year high of $60.20. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.51 and a quick ratio of 1.77. The company has a market capitalization of $10.04 billion, a PE ratio of -9.10, a P/E/G ratio of 6.64 and a beta of 1.20. The company has a fifty day moving average of $55.66 and a 200 day moving average of $52.65.

Catalent (NYSE:CTLTGet Free Report) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $0.21 by ($0.36). The company had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.11 billion. Catalent had a negative net margin of 26.61% and a negative return on equity of 2.73%. Research analysts forecast that Catalent will post 0.28 earnings per share for the current year.

Insider Buying and Selling at Catalent

In related news, insider Ricky Hopson sold 1,401 shares of the company’s stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $54.26, for a total value of $76,018.26. Following the sale, the insider now directly owns 20,617 shares of the company’s stock, valued at $1,118,678.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.31% of the company’s stock.

Hedge Funds Weigh In On Catalent

Large investors have recently bought and sold shares of the stock. Vanguard Personalized Indexing Management LLC grew its holdings in Catalent by 5.5% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 8,485 shares of the company’s stock worth $386,000 after acquiring an additional 446 shares during the period. Pathstone Family Office LLC bought a new stake in shares of Catalent in the 3rd quarter worth approximately $374,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in Catalent by 15.4% during the third quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 36,247 shares of the company’s stock valued at $1,650,000 after purchasing an additional 4,839 shares during the last quarter. Envestnet Portfolio Solutions Inc. bought a new stake in Catalent during the third quarter worth approximately $3,553,000. Finally, Envestnet Asset Management Inc. grew its position in Catalent by 47.4% in the third quarter. Envestnet Asset Management Inc. now owns 402,172 shares of the company’s stock worth $18,311,000 after buying an additional 129,385 shares during the last quarter.

Catalent Company Profile

(Get Free Report)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.

Read More

Analyst Recommendations for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.